IMMP Immutep Limited

1.07
-0.01  -1%
Previous Close 1.08
Open 1.06
Price To Book 2.28
Market Cap 41,601,343
Shares 38,879,760
Volume 177,025
Short Ratio
Av. Daily Volume 636,625
Stock charts supplied by TradingView

NewsSee all news

  1. Immutep Announces First INSIGHT-004 Data and New TACTI-002 Data to be Included in Poster Presentations During the ASCO 2020 Annual Meeting

    SYDNEY, Australia, April 30, 2020 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company") is pleased to announce new data are scheduled to be presented in two poster presentations

  2. Immutep Reports Positive Phase II TACTI-002 Data

    Increasing benefit reported from patients with first line Non-Small Cell Lung Cancer (NSCLC):    º Improving Overall Response Rate (ORR) of 53% (earlier data indicated 47%)    º Improving Progression free Survival (PFS)

  3. Enrollment completed for the INSIGHT-004 Study

    SYDNEY, Australia, April 22, 2020 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a biotechnology company developing novel immunotherapy treatments for cancer and

  4. Immutep Advances Cell Line Development for IMP761

    SYDNEY, Australia, April 16, 2020 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), is pleased to announce that Batavia Biosciences, its manufacturing partner for its

  5. Immutep TACTI-002 Data Presentation at the AACR Virtual Annual Meeting 2020

    SYDNEY, Australia, April 14, 2020 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a biotechnology company developing novel immunotherapy treatments for cancer and

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2b overall survival data due late-2020. 63% of patients were progression-free at 6 months compared with 54% on placebo (HR 0.93)
Eftilagimod Alpha - Active Immunotherapy PAClitaxel (AIPAC)
Metastatic breast cancer (MBC)
Phase 1 final safety data due 2H 2020.
Eftilagimod alpha and Keytruda (TACTI-mel)
Melanoma
Phase 2 initial data to be presented at ASCO May 29, 2020.
Eftilagimod alpha and Keytruda - TACTI-002 (ASCO)
Non-small cell lung cancer; Head and neck cancer
Phase 1 initial data to be presented 2Q 2020.
Eftilagimod alpha - INSIGHT-004
Solid tumors
Phase 2 trial to be completed August 2022.
GSK2831781
Ulcerative Colitis

Latest News

  1. Immutep Announces First INSIGHT-004 Data and New TACTI-002 Data to be Included in Poster Presentations During the ASCO 2020 Annual Meeting

    SYDNEY, Australia, April 30, 2020 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company") is pleased to announce new data are scheduled to be presented in two poster presentations

  2. Immutep Reports Positive Phase II TACTI-002 Data

    Increasing benefit reported from patients with first line Non-Small Cell Lung Cancer (NSCLC):    º Improving Overall Response Rate (ORR) of 53% (earlier data indicated 47%)    º Improving Progression free Survival (PFS)

  3. Enrollment completed for the INSIGHT-004 Study

    SYDNEY, Australia, April 22, 2020 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a biotechnology company developing novel immunotherapy treatments for cancer and

  4. Immutep Advances Cell Line Development for IMP761

    SYDNEY, Australia, April 16, 2020 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), is pleased to announce that Batavia Biosciences, its manufacturing partner for its

  5. Immutep TACTI-002 Data Presentation at the AACR Virtual Annual Meeting 2020

    SYDNEY, Australia, April 14, 2020 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a biotechnology company developing novel immunotherapy treatments for cancer and

  6. Immutep's Partner, EOC Pharma, Continues to Advance Efti in Breast Cancer

  7. Immutep Reports Supportive Efficacy Data from the Phase IIb AIPAC Study; Overall Survival Data Expected in Late 2020

    Progression Free Survival (PFS) Hazard Ratio improvement for eftilagimod alpha (efti) group versus placebo at the 6-month landmarkIncreased Overall Response Rate (ORR) of 48.3% in the efti group versus 38.4% in the

  8. Immutep's Partner, EOC Pharma, Reports Completion of Recruitment of Phase I Study of Efti

    Last patient enrolled and safely dosed, completing patient recruitment for EOC Pharma's phase I study in metastatic breast cancer (MBC)Data expected throughout 2020, with study completion in Q4 CY2020Registration trial

  9. Immutep Receives Second IND approval for Efti from US FDA

    Enables Immutep to initiate its AIPAC-002 study, in metastatic breast cancerAIPAC-002 to expedite the possible use of efti for patients in the US SYDNEY, Australia, March 09, 2020 (GLOBE NEWSWIRE) --  Immutep

  10. WuXi Biologics Congratulates Immutep on Positive Interim Data for IMP-321

    SHANGHAI, Feb. 23, 2020 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development

  11. Immutep Reports Positive TACTI-002 Data

    Encouraging Overall Response Rates (ORR) reported from stage 1 Parts A and C, with responses in 47% of 1st line non-small cell lung cancer (NSCLC) patients and already 33% of 2nd line head and neck squamous cell

  12. Immutep to Present TACTI-002 Interim Data at German Cancer Congress

    SYDNEY, Australia, Feb. 04, 2020 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a biotechnology company developing novel immunotherapy treatments for cancer and

  13. Immutep Activities Report

    First progression-free survival ("PFS") data expected from late-stage Phase IIb metastatic breast cancer study, AIPAC, in March 2020More mature data expected from TACTI-002 in February 2020Sufficiently funded to deliver

  14. Immutep Expands Part C of TACTI-002 Due to Positive Data

    Recruitment completed for stage 1 of Part C of TACTI-002 trial, for patients with second line Head and Neck Squamous Cell Carcinoma (HNSCC)Part C has been expanded to include an additional 19 HNSCC patients, creating

  15. INSIGHT-004 Clinical Trial Update

    Recruitment commenced for second cohort of 6 patients at higher efti dose combined with avelumabNo new safety signals in the first cohort, with 1 patient reporting a partial responseMore data expected to be reported in

  16. Immutep Announces European Patent Grant for LAG525 Antibody

    SYDNEY, Australia, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company") is pleased to announce the grant of patent no. 3116909 entitled "Antibody molecules to

  17. Immutep Presents Positive Interim Data From Phase II TACTI-002 Trial at SITC

    Part A comprises NSCLC patients with all levels of PD-L1 expression, being an all comer trialPreliminary Overall Response Rate (ORR) of 41% from stage 11 of Part A  ORR compares favourably to standard of care treatments

  18. Immutep Reports Positive Final Efficacy Data from TACTI-mel Trial in Melanoma

    Key Trial Findings Favourable safety profile of eftilagimod alpha in combination with pembrolizumabDeep and durable responses have been observed with tumour shrinkage in 56% and 66% of patients in part A and B

  19. Immutep Receives A$2.5 Million R&D Tax Incentive from French Government

    SYDNEY, Australia, Oct. 10, 2019 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a biotechnology company developing novel immunotherapy treatments for cancer and

  20. Immutep Announces Data Presentations at Upcoming Industry Conferences

    SYDNEY, Australia, Oct. 10, 2019 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a biotechnology company developing novel immunotherapy treatments for cancer and

  21. Immutep Announces Expansion of Part A of TACTI-002 Phase II Clinical Trial due to Positive Interim Data

    Requisite clinical responses achieved in cohort 1 of Part A (1st line NSCLC) of TACTI-002 Phase II clinical trial to allow for recruitment of cohort 2Recruitment of cohort 2 of Part A of TACTI-002, additional 19

  22. Immutep to Receive £4M Milestone Payment From GSK

    SYDNEY, Australia, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a biotechnology company developing novel immunotherapy treatments for cancer and

  23. Immutep Announces Japanese Patent Grant for LAG525 Antibody

    SYDNEY, Australia, Sept. 17, 2019 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company") is pleased to announce the grant of patent no. 6576962 entitled "Antibody molecules to

  24. Immutep Granted European Patent for Eftilagimod Alpha in Cancer

    SYDNEY, Australia, Aug. 22, 2019 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a biotechnology company developing novel immunotherapy treatments for cancer and